Dragonfly Therapeutics, Inc.

Proudly presenting our Phase 1/1b, First-in-Human, multi-part study of DF6215, an engineered IL-2Rα-active agonist for advanced solid tumors, in the Developmental Therapeutics-Immunotherapy poster session at American Society of Clinical Oncology (ASCO) with Benedito A. Carneiro, MD, MS, Brown University #ASCO24

Dragonfly is in Chicago! #ASCO24

We have entered into a clinical collaboration with Merck to evaluate DF9001, our EGFR immune engager, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors expressing EGFR. https://lnkd.in/eErs3u3n

We're super proud to be in the top 3 Best Biotech Startup Employers in the Boston area by @Forbes for 2024! 3000 privately-held Startup companies were evaluated on 3 primary criteria: company reputation, employee satisfaction and growth (each Startup must also have been started from scratch, founded between 2014 and 2021, headquartered in the U.S., and have more than 50 employees). https://lnkd.in/gic_9qPz

First Patient dosed in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303 in solid tumors. This is the sixth TriNKET® and the eighth Dragonfly drug to enter into clinical trials! https://lnkd.in/dXibkKrc

We are thrilled to announce a new clinical collaboration with #Gilead, combining DF1001, our HER-2 immune engager, with Trodelvy, Gilead's Trop-2-directed antibody drug conjugate (ADC), for two cancer indications. https://lnkd.in/e4TQwHbC

We moved! So wonderful to all be together under one roof, in a beautiful new facility. Ribbon Cutting Ceremony & Celebration today, with CEO Bill Haney holding the big scissors and doing the honors.

First patient dosed in a Phase 1/1b clinical trial of our novel IL-2 cytokine, DF6215, the 7th Dragonfly-developed drug to enter into clinical trials! https://lnkd.in/gm5PA4Gd

Five years ago, Ward Thrasher was diagnosed with Stage 4 colon cancer. In December 2022 he was the first person in the world to be given Dragonfly’s EGFR TriNKET. It’s the fifth time Mr. Thrasher has participated in a clinical trial; he received the lowest starting dose of our EGFR-targeting TriNKET, and is experiencing good quality of life, no side effects, and some tumor shrinkage. Our hope for Mr. Thrasher and other patients on our EGFR trial as we approach our targeted dose is to see ever-increasing patient benefits. We admire and thank patients like Mr. Thrasher for their courage in participating in clinical trials critical to advancing life-saving therapies. https://lnkd.in/eNzf7jHt

What an amazing way to honor our female founders! https://lnkd.in/e6iSJcac